Yujia Niu
Xiamen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma.
Journal: Clinical and translational medicine
Published: September 30, 2025
Erratum: Author correction to "PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism" [Acta Pharm Sin B 13 (2023) 157-173].
Journal: Acta pharmaceutica Sinica. B
Published: June 09, 2025
Ursodeoxycholic acid inhibits the uptake of cystine through SLC7A11 and impairs de novo synthesis of glutathione.
Journal: Journal of pharmaceutical analysis
Published: March 19, 2024
Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma.
Journal: Frontiers of medicine
Published: December 22, 2022
The glycolysis/HIF-1α axis defines the inflammatory role of IL-4-primed macrophages.
Journal: Cell reports
Published: November 02, 2022
Themis is indispensable for IL-2 and IL-15 signaling in T cells.
Journal: Science signaling
Published: February 15, 2022
PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism.
Journal: Acta pharmaceutica Sinica. B
Published: January 15, 2022
Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer.
Journal: Nature cancer
Published: April 26, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026